News from Visiopharm


New APP: Hot Spot

Eliminate intra- and inter-observer variability, save time, increase accuracy, keep flexibility with a full configurable APP for hot spot analysis, gain an easy overview of whole slide tumor heterogeneity with heatmap visualization.

CE-marked for In Vitro Diagnostics
The clinical performance of the APP was validated in collaboration with:
Karolinska Institutet, Sweden
Pathology Diagnostics Jarutat, Germany
Nap Pathology Consultance, The Netherlands

Explore the Hot Spot APP

New APP: Invasive Tumor Detection (PDS)

Eliminate manual annotations, increase accuracy, save hours, increase efficiency with a CE-IVD validated tool!

CE-marked for in vitro diagnostics
The clinical performance of the APP was validated in collaboration with:
Odense University Hospital, Denmark
Pathology Diagnostics Jarutat, Germany
University Medical Center Groningen, The Netherlands

Explore the Invasive Tumor Dectection APP

LAUNCHING: AI Powered by Deep Learning for Image Analysis

Do you have an interest in saving time, automate cell identification, segmentation, and quantification? Take a look!

The Oncotopix®/Biotopix™ AI image analysis platform is now powered by the latest technological breakthroughs in AI and deep learning, providing the most comprehensive solution for image analysis available for Digital Pathology today.

Explore AI image analysis powered by deep learning 

 

 

Fluidigm Announces Co-Marketing Agreement with Visiopharm

Together with Fluidigm we'll expand and simplify imaging mass cytometry data analysis. 

“The collaboration between Fluidigm and Visiopharm will provide scientists novel tools to understand the biology of cancer, including the phenotyping of cells within the tumor microenvironment,” said Michael Grunkin, CEO of Visiopharm. “Our complementary technologies provide an entirely new research approach to drive drug-diagnostic co-development on a tissue-based platform, with the potential to also provide a new framework for precision medicine in cancer.”

Read press release here

 

New APP: PD-L1, Cell Lines, Cancer

This APP can be used for quality control of PD-L1 strong positive, intermediate positive, weak positive and negative cell line material to ensure that each cell line block complies with the expected PD-L1 expression before the material is used as reference standard for IHC assays. The APP quantifies the PD-L1 expression in each cell line core and relates this expression to a known reference value for each cell line expression level.

For more information visit our APP Center

Sign up to our newsletter
* indicates required
Are you a current customer
 

Visiopharm quantitative digital pathology solutions provide pathologists and scientists with a flexible, powerful suite of software to quantify relevant tissue properties in a fast, objective and reproducible way.

Learn more about us

Visit our APP center

The world's largest and fastest growing

Visit the complete app center

Publications

Visiopharm software is featured in over 1300 international scientific publications. They are based on collaborations with leading scientists in hospitals, biopharmaceutical companies and research institutions around the world. Select a main category to access the publication list.